Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging…

Why are Telix shares trading higher today?

Shares in Telix Pharmaceuticals Ltd (ASX: TLX) were trading higher on Wednesday after the company said it had filed a key regulatory approval in Europe. Telix, in a statement to the ASX, said it had submitted a marketing authorisation application (MAA) in Europe for its brain cancer imaging candidate, TLX101-Px. Dual regulatory process on foot The company said it had been preparing the regulatory packages for Europe and the US concurrently and w…